UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 18, 2021, Zoetis Inc. (the “Company”) announced that Dr. Catherine Knupp, DVM, MS, the Company’s Executive Vice President and President of Research & Development, has provided notice of her intention to retire from her position, effective December 31, 2021, and that the Company has appointed Robert J. Polzer, PhD, who currently serves as the Company’s Senior Vice President of Global Therapeutics, to succeed Dr. Knupp as the Company’s Executive Vice President and President of Research & Development, effective January 1, 2022. The Company and Dr. Knupp expect Dr. Knupp to remain with the Company as an advisor assisting with the transition of her duties from January 1, 2022 until February 28, 2022.
Item 8.01. Other Events.
On October 18, 2021, the Company issued a press release announcing the appointment of Dr. Polzer and the retirement of Dr. Knupp. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following Exhibits are filed herewith as part of this report:
| Exhibit No. | Description | |
| 99.1 | Press Release dated as of October 18, 2021. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| ZOETIS INC. | ||||
| By: | /s/ Heidi C. Chen | |||
| Name: | Heidi C. Chen | |||
| Title: | Executive Vice President, General Counsel and Corporate Secretary | |||
Dated: October 18, 2021
-3-